HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

vofatamab

an IgG1antibody to FGFR3 for the treatment of t(4;14)-positive multiple myeloma

Also Known As:

MFGR-1877A; MFGR-1877S; MFGR1877A; MFGR1877S; RG-7444

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Brady, Ann: 1 article (04/2012)
2.	Damico-Beyer, Lisa A: 1 article (04/2012)
3.	Gupta, Priyanka: 1 article (04/2012)
4.	Jin, Denise: 1 article (04/2012)
5.	Kamath, Amrita V: 1 article (04/2012)
6.	Li, Hao: 1 article (04/2012)
7.	Lu, Dan: 1 article (04/2012)
8.	Qing, Jing: 1 article (04/2012)
9.	Stephan, Jean-Philippe: 1 article (04/2012)
10.	Tien, Janet: 1 article (04/2012)

Related Diseases

1.

Multiple Myeloma

04/01/2012 - "The PK of MFGR1877A in mice was non-linear in the dose range of 1-50 mg/kg, while in rats and monkeys, PK was non-linear in the dose range of 1-10 mg/kg and linear at doses ≥ 10 mg/kg. The predicted non-specific clearance range in humans was 2.6-4.4 mL/day/kg. Doses ranging from 2 to 3 mg/kg weekly to 6-10 mg/kg every 4 weeks were predicted to achieve the target exposure in ≥ 90% of multiple myeloma patients. "
04/01/2012 - "Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma."
04/01/2012 - "MFGR1877A is a human IgG1 monoclonal antibody that binds to fibroblast growth factor receptor 3 (FGFR3) and is being investigated as a potential therapy for relapsed/refractory FGFR3+ multiple myeloma. "

Related Drugs and Biologics

1.	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)
2.	Immunoglobulin G (IgG)
3.	Monoclonal Antibodies

Related Therapies and Procedures

1.	Therapeutics